CAR T-Cell Therapy for EBV-Associated Hematopoietic Malignancies

In recent years, cancer therapy has advanced from chemotherapy and targeted therapy to immuno-therapy, thus resolving drug specificity-related problems pertaining to tumor cells and resistance. Chi-meric antigen receptor (CAR) T cells are genetically modified T cells that express receptors for specific tumor cell antigens to induce T-cell-mediated cytotoxicity. Therefore, the identification of specific anti-gens on tumor cells is a key point that should be considered in CAR T-cell therapy. For instance, Epstein -Barr virus expresses the oncoprotein latent membrane protein 1 to induce various diseases such as na-sopharyngeal carcinoma; posttransplant lymphoproliferative disorders; and diffuse large B-cell, Bur -kit t, and Hodgkin lymphomas.Copyright (c) 2023, Taiwan Society of Geriatric Emergency & Critical Care Medicine.